Dr Geetha Manjunath is the founder and CEO of NIRAMAI Health Analytix, a Bengaluru health-tech company. Its AI-based test screens women for breast cancer without radiation, contact or pain. Geetha spent more than 25 years in computing research before starting it, and was driven by a personal loss.
Who is Geetha Manjunath, and what is NIRAMAI? Geetha Manjunath is a computer scientist with a PhD from IISc who left a senior AI research role to co-found NIRAMAI with Nidhi Mathur. NIRAMAI’s core product, Thermalytix, combines thermal imaging with machine learning to detect early signs of breast cancer. According to the company, it has screened more than 500,000 women across more than 22 countries.
Who is Geetha Manjunath? Background
Geetha earned a PhD in Computer Science from the Indian Institute of Science (IISc), Bengaluru, and later completed a management programme at Kellogg School of Management. Her career ran through India’s major technology labs:
- CDAC: early work in advanced computing.
- HP Labs: led research in analytics and machine learning.
- Xerox Research: Lab Director, heading AI research.
The turning point was personal. Within a short span, two of her cousins were diagnosed with late-stage breast cancer. As she told YourStory:
“Within six months, both my cousins, Bharti and Lakshmi, who were diagnosed at stage four and lost their lives.”
She began asking why breast cancer in India is so often caught late, and whether the AI she had spent her career building could help.
The business idea: “no see, no touch, no pain, no radiation”
Mammography, the standard screening test, is expensive, needs specialist equipment and radiologists, uses low-dose radiation and works less well in the denser breast tissue common in younger women. Many Indian women also avoid screening out of privacy concerns.
NIRAMAI’s answer is Thermalytix:
- A thermal camera captures heat patterns from a distance, with no contact.
- AI algorithms analyse the thermal images and flag abnormal patterns that may point to a tumour.
- The test needs no radiation, is private and portable, and can run in camps, clinics and workplaces.
The company sums it up as “no see, no touch, no pain, no radiation.” YourStory has reported company claims that the approach is about 30% more accurate than conventional methods, at about 20% of the cost.
Challenges
- Clinical proof: a new screening method has to be validated through hospital studies before doctors trust it.
- Regulatory approvals: medical devices and AI software need certifications in each market.
- Awareness and stigma: getting women, especially in smaller towns, to come for screening at all.
- Funding deep tech: healthcare AI takes years and significant capital before it earns revenue.
Growth journey: key milestones
| Stage | Milestone |
|---|---|
| Founding | NIRAMAI set up in Bengaluru by Geetha Manjunath and Nidhi Mathur |
| Funding | About US$7 million raised from investors (reported by YourStory, 2019) |
| 2025 | YourStory reports 2.5 lakh+ women screened across 22 countries |
| Today | Company reports 500,000+ women screened and 10,000+ screening camps in 22+ countries |
Leadership lessons from Geetha Manjunath
- Turn grief into purpose. A family tragedy became a mission to change outcomes for millions of women.
- Use your deepest skill. She didn’t chase a trend; she applied 25 years of AI research to a problem she understood.
- Design for the real user. Privacy, cost and comfort matter as much as accuracy for women in India.
- Prove it clinically. In healthcare, trust comes from evidence, not marketing.
- It’s never too late to start. Geetha became a founder after a long corporate career.
See more founders turning technology into impact in our features on women entrepreneurs in India and social entrepreneurs in India.
What’s next for NIRAMAI
NIRAMAI aims to make breast cancer screening routine and affordable, through more screening camps, corporate and government programmes, and expansion into other countries. It is also exploring how the thermal AI platform could be used for other health conditions.
FAQs
Who is the founder of NIRAMAI?
Dr Geetha Manjunath is the founder and CEO of NIRAMAI Health Analytix. She co-founded it with Nidhi Mathur in Bengaluru.
What is Thermalytix?
Thermalytix is NIRAMAI’s AI-based breast cancer screening test. It analyses thermal images of the chest without radiation, contact or pain.
Why did Geetha Manjunath start NIRAMAI?
Two of her cousins died after being diagnosed with stage-four breast cancer. That loss pushed her to build a screening test that could catch cancer earlier.
How many women has NIRAMAI screened?
The company reports screening more than 500,000 women through more than 10,000 camps in over 22 countries.
Is NIRAMAI’s test a replacement for mammography?
Thermalytix is a screening tool. Women flagged as at-risk are referred for further diagnostic tests. Anyone with concerns should consult a doctor.
Conclusion
The Geetha Manjunath and NIRAMAI story shows how deep research skill, personal motivation and a focus on real users can produce a health innovation that reaches women whom traditional screening often misses.
Sources
- YourStory HerStory: Geetha Manjunath and NIRAMAI (2025)
- YourStory Techie Tuesday: Geetha Manjunath (2019)
- NIRAMAI: About us
Last updated: November 2026
